Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 2/20 | 0.45 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.44 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 5/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | FLT1 | P17948 | 1/20 | 0.39 |
| ▸ | FLT4 | P35916 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | FABP4 | P15090 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12748641 | 0.84 | AKR1C3 (0.56) | ACLYCA2CA9HTR6RORC | |
| SCHEMBL12748713 | 0.84 | HTR6 (0.54) | PTGDR2PTGDRHTR6KCNH2AKR1C3 | |
| SCHEMBL12748722 | 0.80 | AKR1C3 (0.48) | ACLYHTR6AKR1C3AKR1C1FABP4 | |
| SCHEMBL12748717 | 0.78 | AKR1C3 (0.46) | ACLYHTR6AKR1C3AKR1C1FABP4 | |
| SCHEMBL14037139 | 0.78 | FABP4 (0.46) | PTGDR2PTGDRHTR6AKR1C3AKR1C1 | |
| SCHEMBL1468385 | 0.78 | AKR1C3 (0.60) | PTGDR2PTGDRHTR6AKR1C3AKR1C1 | |
| SCHEMBL3132223 | 0.76 | AKR1C3 (0.58) | ACLYCA2CA9HTR6AKR1C3 | |
| SCHEMBL15556917 | 0.76 | HTR3A (0.57) | PTGDR2HTR6RORCAKR1C3AKR1C1 | |
| SCHEMBL12748697 | 0.76 | AKR1C3 (0.68) | PTGDR2HTR6AKR1C3AKR1C1SMN1; SMN2 | |
| SCHEMBL1466360 | 0.75 | AKR1C3 (0.60) | ACLYHTR6AKR1C3AKR1C1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110071146-A1 | 17BetaHSD Type 5 Inhibitor | ASTELLAS PHARMA INC. | 2011-03-24 | — | — | US | disclosed |
| US-7855225-B2 | 17βHSD type 5 inhibitor | ASTELLAS PHARMA INC. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-7855225-B2 | 17βHSD type 5 inhibitor | ASTELLAS PHARMA INC. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-20090181960-A1 | Selective enzyme inhibitors of 17-beta-hydroxysteroid dehydrogenase (17 beta HSD); 1-[(4-bromophenyl)sulfonyl]-1H-indole-3-carboxylic acid, andanalogues; benign prostate hyperplasia; prostate cancer; acne, seborrhea, hirsutism, baldness, alopecia, precocious puberty, adrenal hypertrophy, breast cancer | ASTELLAS PHARMA INC. (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090181960-A1 | Selective enzyme inhibitors of 17-beta-hydroxysteroid dehydrogenase (17 beta HSD); 1-[(4-bromophenyl)sulfonyl]-1H-indole-3-carboxylic acid, andanalogues; benign prostate hyperplasia; prostate cancer; acne, seborrhea, hirsutism, baldness, alopecia, precocious puberty, adrenal hypertrophy, breast cancer | ASTELLAS PHARMA INC. (JP) | 2009-07-16 | — | — | US | disclosed |
| EP-1990335-A1 | 17 BETA HSD TYPE 5 INHIBITOR | Astellas Pharma Inc. (JP) | 2008-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071146-A1 | 17BetaHSD Type 5 Inhibitor | CYP17A1, HSD17B3, HSD3B1 | ACLY 1484/4885PTGDR2 1268/4885PTGDR 875/4885 |
| US-20090181960-A1 | Selective enzyme inhibitors of 17-beta-hydroxysteroid dehydrogenase (17 beta HSD); 1-[(4-bromophenyl)sulfonyl]-1H-indole-3-carboxylic acid, andanalogues; benign prostate hyperplasia; prostate cancer; acne, seborrhea, hirsutism, baldness, alopecia, precocious puberty, adrenal hypertrophy, breast cancer | CYP17A1, HSD17B3, HSD17B1 | ACLY 903/4885PTGDR2 1448/4885PTGDR 1031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.